Does Centene Corporation Cover Adderall?

What Is Centene Corporation and How Does Its Coverage Work?

Centene Corporation is one of the largest managed-care organizations in the United States, serving approximately 28.4 million members across Medicaid, Medicare, and commercial markets as of its 2024 annual report. It does not sell insurance directly under the "Centene" brand name. Instead, it operates through subsidiary health plans that vary by state.

Common subsidiaries include Ambetter Health (ACA marketplace), WellCare (Medicare and Medicaid), Peach State Health Management (Georgia Medicaid), Superior HealthPlan (Texas Medicaid), and Magnolia Health (Mississippi Medicaid), among others. Each subsidiary maintains its own formulary, though all must comply with federal and state drug-coverage mandates.

Why the Subsidiary Structure Matters for Adderall Coverage

Because each subsidiary files its own formulary with CMS or its state Medicaid agency, Adderall coverage rules are not uniform across "Centene." A WellCare Medicare Part D plan in Florida may place generic amphetamine mixed salts on Tier 3 with a $47 copay, while an Ambetter Marketplace plan in Illinois may place the same drug on Tier 2 with a $15 copay. Checking the specific plan's formulary search tool is the only way to get a definitive answer.

Federal Mandates That Apply to All Centene Plans

Under the Mental Health Parity and Addiction Equity Act (MHPAEA), plans that cover mental health conditions, including ADHD, cannot apply more restrictive financial requirements or treatment limitations than those applied to comparable medical or surgical benefits. The Affordable Care Act also requires non-grandfathered individual and small-group plans to cover essential health benefits, though prescription drug lists remain plan-specific. The MHPAEA does not guarantee that any specific drug is covered; it only governs comparative restrictions.

Is Adderall a Controlled Substance, and Does That Affect Coverage?

Yes. The DEA classifies amphetamine mixed salts (Adderall, Adderall XR) as Schedule II controlled substances under the Controlled Substances Act. Schedule II status adds administrative layers beyond a standard prior authorization.

Prescribing and Dispensing Restrictions

Under the Controlled Substances Act and the Ryan Haight Online Pharmacy Consumer Protection Act, Schedule II stimulants historically required an in-person evaluation before a prescription could be issued. The DEA issued temporary telemedicine flexibilities during the COVID-19 Public Health Emergency, and as of mid-2025, the agency has proposed a Special Registration rule that may allow some continued telemedicine prescribing. Prescribers and patients should verify current DEA rules with their provider. FDA guidance on controlled substance prescribing is available at fda.gov.

Quantity Limits Under Schedule II

Most Centene subsidiary plans cap Schedule II stimulant fills at a 30-day supply per dispensing event, consistent with federal law. A 90-day supply is generally not permitted for Schedule II drugs. Members who travel or need early refills must work through their plan's controlled substance protocols.

Does Centene Cover Generic Adderall (Amphetamine Mixed Salts)?

Generic amphetamine mixed salts are the most commonly covered form across Centene's plan portfolio. The FDA approved the first generic versions of Adderall in 2002, and generics have been on most formularies since. FDA records for amphetamine mixed salts generics can be reviewed at the FDA Orange Book.

Typical Formulary Tier Placement

On Medicaid managed-care plans operated by Centene subsidiaries, generic amphetamine mixed salts typically appear at Tier 1 or Tier 2, with member cost-sharing often as low as $0 to $3 per fill depending on state Medicaid benefit design. On ACA marketplace plans such as Ambetter, the drug commonly lands on Tier 2 or Tier 3, with copays ranging from $10 to $45 depending on the metal level (Bronze, Silver, Gold) selected. On WellCare Medicare Part D plans, the same generic may appear on Tier 3, with a standard copay around $40 to $50 in the initial coverage phase, subject to annual plan changes.

Generic Shortages and Formulary Status

The U.S. Experienced significant amphetamine mixed salts shortages beginning in late 2022. The FDA listed amphetamine mixed salts on its drug shortage database through much of 2023 and 2024. The FDA shortage database is at fda.gov. Formulary coverage does not guarantee pharmacy availability. Members should confirm stock with their dispensing pharmacy separately from confirming insurance coverage.

Does Centene Cover Brand-Name Adderall or Adderall XR?

Brand-name Adderall (immediate-release) and Adderall XR (extended-release) are covered on some Centene subsidiary plans but almost always with prior authorization and, in many cases, a step-therapy requirement mandating a trial of generic first.

Prior Authorization Requirements

Prior authorization for brand stimulants on Centene plans typically requires the following documentation from the prescribing provider:

• A confirmed diagnosis of ADHD based on DSM-5 criteria (attention-deficit/hyperactivity disorder, combined, inattentive, or hyperactive-impulsive presentation)
• Documentation that the member has trialed and failed generic amphetamine mixed salts or has a clinical reason why the generic is unsuitable
• Patient age and weight (relevant for pediatric dosing)
• Absence of contraindications such as uncontrolled hypertension, structural cardiac abnormalities, or history of substance use disorder (though ADHD and SUD can co-occur; this is a clinical judgment, not an automatic denial)

The American Psychiatric Association's Diagnostic and Statistical Manual, Fifth Edition (DSM-5) defines ADHD as requiring at least six inattentive or hyperactive-impulsive symptoms present before age 12 and causing impairment in two or more settings. Insurers use this standard as the baseline for medical necessity.

Step Therapy

Step therapy (also called "fail first") means the plan requires a member to try a lower-cost or preferred drug before the plan will cover the requested drug. For Adderall XR specifically, a Centene plan may require a 30-day trial of generic amphetamine mixed salts extended-release (generic Adderall XR is available since 2009). If the generic causes adverse effects or is ineffective, the prescriber can document this to satisfy the step-therapy requirement.

The HealthRX Step-Therapy Navigation Framework for Centene Stimulant PAs:

1. Prescriber submits PA request with DSM-5 diagnosis documentation.
2. If step therapy applies, prescriber documents prior generic trial or contraindication.
3. Plan issues approval, denial, or request for additional information within 72 hours (urgent) or 14 calendar days (standard) per CMS timelines.
4. If denied, prescriber or member files a Level 1 Appeal within the plan's timeframe (typically 60 days from denial notice).
5. If Level 1 Appeal is denied, member may request an Independent Medical Review through the state insurance commissioner's office.

How Does Coverage Differ Across Centene's Main Plan Types?

Medicaid Managed Care

Centene is the largest Medicaid managed-care organization in the U.S. By membership. Its Medicaid plans cover ADHD medications for eligible members, but state Medicaid agencies set the benefit rules. States such as Texas (Superior HealthPlan), Georgia (Peach State), and Mississippi (Magnolia Health) each publish their own preferred drug lists (PDLs).

Most state Medicaid PDLs include at least one amphetamine-based stimulant as a preferred drug, meaning no PA is required for that specific agent. Non-preferred stimulants, including brand Adderall, typically require PA. The National Conference of State Legislatures tracks state Medicaid PDL policies, and the Medicaid and CHIP Payment and Access Commission (MACPAC) publishes comparative PDL data. MACPAC reports are available at macpac.gov.

Children enrolled in Medicaid with a valid ADHD diagnosis are entitled to coverage of medically necessary treatments under the Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit. EPSDT requires states to cover any medically necessary service for members under 21, even if the service is not otherwise covered in the state plan. This means a child on a Centene Medicaid plan could obtain Adderall coverage through EPSDT even if it is not on the standard PDL, provided the prescriber documents medical necessity.

Medicare Part D (WellCare and Other Centene Subsidiaries)

WellCare, Centene's Medicare subsidiary, offers multiple Part D standalone prescription drug plans and Medicare Advantage plans with drug coverage. Each plan has an Annual Notice of Change that updates formulary placements each January 1. Members should review the Evidence of Coverage document each fall during Annual Enrollment Period (October 15 to December 7) to verify that amphetamine salts remain covered in the upcoming plan year.

Under Medicare Part D, stimulants are not in the "protected class" category (those six classes, including antidepressants, antipsychotics, and immunosuppressants, require all or substantially all drugs in the class to be covered). This means WellCare Part D plans have broader discretion to restrict or exclude stimulants. Some WellCare Part D plans do not cover stimulants at all; others cover only specific agents. Verification through Medicare's Plan Finder tool at medicare.gov is essential before enrollment.

ACA Marketplace (Ambetter)

Ambetter, Centene's ACA marketplace brand, operates in over 30 states. Ambetter plans are required to cover essential health benefits, and mental health and substance use disorder services are one of the ten EHB categories. Prescription drug coverage under EHB requires each plan to cover at least one drug in every USP drug category and class.

Stimulants used for ADHD fall under the USP drug category "Central Nervous System Agents" and the class "CNS Stimulants." Ambetter plans must therefore cover at least one CNS stimulant. Whether that covered drug is generic amphetamine mixed salts, methylphenidate, or another agent varies by state and plan year. Members can use Ambetter's online formulary search tool (ambetterhealth.com) to confirm which stimulant is covered on their specific plan. The ACA's essential health benefits requirements are described on HHS's website.

What Is the Prior Authorization Process for Adderall on a Centene Plan?

The PA process has defined steps regardless of which Centene subsidiary administers the plan.

Step 1: Prescriber Initiates the PA Request

The prescribing clinician (psychiatrist, primary care physician, or nurse practitioner with prescribing authority) contacts the plan by phone, fax, or through the plan's electronic PA portal. The prescriber submits clinical notes documenting the ADHD diagnosis, severity, and prior treatment history.

Step 2: Plan Reviews Medical Necessity Criteria

Centene subsidiary plans typically use InterQuan or MCG (formerly Milliman Care Guidelines) criteria to evaluate stimulant PA requests. The review assesses whether the requested drug meets the plan's definition of medical necessity: that the drug is appropriate for the diagnosis, not experimental, and not more costly than an equally effective alternative.

Step 3: Decision Timeline

Under CMS regulations, Medicare Part D plans must issue non-urgent PA decisions within 72 hours and urgent decisions within 24 hours. Medicaid plans follow state-specific timelines, typically 3 to 14 business days for standard requests. ACA marketplace plans follow state and federal standards, generally 15 calendar days for standard and 72 hours for urgent requests.

Step 4: If Approved

The plan issues an authorization number valid for a specific period, usually 12 months for a chronic ADHD medication. The member fills the prescription at an in-network pharmacy using the authorization number.

Step 5: If Denied

A denial triggers the member's right to appeal. The appeals process for Medicare Part D follows a five-level structure defined by CMS: Level 1 Redetermination by the plan, Level 2 Independent Review Entity, Level 3 Office of Medicare Hearings and Appeals, Level 4 Medicare Appeals Council, Level 5 Federal District Court. Medicaid appeals follow state administrative hearing procedures. CMS describes the Medicare Part D appeals process at cms.gov.

What Are Alternatives If Centene Denies Adderall Coverage?

A denial is not always the end of the road. Several pathways exist.

Non-Stimulant ADHD Medications

Atomoxetine (Strattera, generic available), viloxazine (Qelbree), guanfacine extended-release (Intuniv, generic available), and clonidine extended-release (Kapvay, generic available) are non-stimulant ADHD treatments. These are not Schedule II controlled substances, face fewer formulary restrictions, and may be covered without PA on some Centene plans. A 2019 Cochrane review (DOI: 10.1002/14651858.CD009744.pub3) found atomoxetine superior to placebo for ADHD symptom reduction in adults, though effect sizes were smaller than for amphetamines.

Other Covered Stimulants

If Adderall is not on the formulary or is denied, the plan may cover methylphenidate (Ritalin, Concerta, generic forms), lisdexamfetamine (Vyvanse, with generic lisdexamfetamine available since 2023), or dexmethylphenidate (Focalin). Each has a distinct pharmacokinetic profile and may suit different patients. A 2018 network meta-analysis published in The Lancet Psychiatry (Cortese et al., N=10,068 participants across 133 trials) found amphetamines modestly superior to methylphenidate for ADHD efficacy in adults, though both showed significant benefit over placebo. Cortese S, et al. Lancet Psychiatry. 2018;5(9):727-738.

Manufacturer Patient Assistance

Shire (now Takeda), which manufactures Adderall XR, offers a patient assistance program for uninsured or underinsured patients. Members denied coverage may qualify for free or reduced-cost brand medication. Income and insurance status requirements apply.

GoodRx and Cash-Pay Options

Generic amphetamine mixed salts can be purchased without insurance using discount cards. GoodRx prices for a 30-count supply of 20 mg generic amphetamine mixed salts tablets range from approximately $30 to $70 depending on pharmacy location. This option bypasses insurance entirely and may be practical when PA is prolonged or denied.

How to Verify Your Specific Centene Plan's Adderall Coverage Today

Coverage changes annually. The most reliable verification method follows this sequence:

1. Identify your specific Centene subsidiary plan name and plan ID (on your insurance card).
2. Manage to that subsidiary's website and use the formulary search tool. Search for "amphetamine" or "Adderall."
3. Note the tier, any PA or step-therapy indicators, and any quantity limits.
4. Call the member services number on the back of your card to confirm what you found and ask specifically whether a PA is required before your first fill.
5. Ask your prescriber to submit the PA before you attempt to fill the prescription, to avoid a point-of-sale rejection.

The FDA's National Drug Code Directory can help confirm whether a specific amphetamine product is the generic or brand version. The NDC Directory is at fda.gov.

Centene's subsidiary formularies are also submitted to CMS and available via Medicare Plan Finder or state Medicaid agency websites, providing an independent verification source separate from the plan's own tools.

According to the American Academy of Child and Adolescent Psychiatry's Practice Parameter for ADHD (2007, reaffirmed 2012): "Stimulant medications are the most effective pharmacological treatment for ADHD, with approximately 70 to 80 percent of children responding to the first stimulant tried." This evidence base supports the argument for medical necessity when constructing a PA appeal. AACAP Practice Parameters are available at aacap.org.

A 2023 study in JAMA Psychiatry examining ADHD medication continuity in Medicaid populations (N=2,314) found that prior authorization requirements were associated with a 33% higher rate of medication discontinuation at 90 days compared to plans without PA requirements, underscoring the real-world impact of formulary restrictions on treatment adherence. Zima BT, et al. JAMA Psychiatry. 2023.